GleamWall
中文EN

TVTX Travere Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1438533 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY49.4%
TTM net income YoY-37.2%
TTM EPS YoY-26.2%
Revenue 3-yr CAGR71.3%
Net income 3-yr CAGR—

Margins

Gross margin98.5%
Operating margin-20.5%
Net margin-18.7%
FCF margin—
EBITDA margin-12.4%

Returns

ROE-252.7%
ROA-17.5%
ROIC (approx.)—
Asset turnover0.94x

Leverage & solvency

Liabilities / assets97.3%
Debt / equity0.00x
Current ratio3.00x
Interest coverage-15.05x

Cash quality & payout

Operating cash flow / net income-1.54x
Accruals ratio-44.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$490.73M$233.18M
Cost of revenue$10.34M$7.74M
Gross profit$480.39M$225.43M
R&D expense$206.01M$217.50M
SG&A expense$337.20M$264.12M
Operating income-$62.82M-$323.83M
Interest expense$10.75M$11.18M
Pretax income-$49.27M-$320.51M
Income tax$988,000$120,000
Net income-$25.55M-$321.55M
EBITDA-$2.08M-$280.27M
EPS (basic)-0.29-4.08
EPS (diluted)-0.29-4.08
Weighted avg. shares (diluted)89.21M78.89M
Balance sheet
Cash & equivalents$93.03M$58.53M
Short-term investments$145.38M—
Receivables$80.13M$27.12M
Inventory$36.16M$41.86M
Current assets$437.56M$416.70M
PP&E, net$4.02M$5.34M
Goodwill—$800,000
Intangibles$113.87M$103.97M
Total assets$605.19M$594.12M
Current liabilities$159.90M$200.75M
Total liabilities$490.36M$535.05M
Shareholders' equity$114.83M$59.08M
Shares outstanding90.92M87.45M
Cash flow statement
Operating cash flow$37.78M-$237.47M
Investing cash flow$27.89M$99.33M
Financing cash flow-$33.47M$139.42M
Depreciation & amortization$60.74M$43.55M
Stock-based compensation$44.87M$36.91M

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.